The risk of cholelithiasis in patients after heart transplantation
- PMID: 24701214
- PMCID: PMC3953977
- DOI: 10.5114/aoms.2014.40733
The risk of cholelithiasis in patients after heart transplantation
Abstract
Introduction: Extended immunosuppressive treatment in patients after heart transplantation modifies etiopathogenesis and occurrence of many diseases in this population. The aim of the present study was to evaluate the frequency and to define risk factors for cholelithiasis after heart transplantation (HTX).
Material and methods: The study population consisted of 176 subjects. Of them, 24 patients (group A) presented with symptomatic cholelithiasis. Another group of 24 patients without cholelithiasis (group B) served as controls. Both groups were similar with respect to age, gender and follow-up after the transplant. Clinical interview, surgical and hospitalization data were collected from medical records.
Results: The groups did not differ in demographic features. There were statistical differences (p < 0.05) between group A and B in rejection reaction, doses of immunosuppressive drugs, type 2 diabetes, serum lipid disorders and acute rejection episodes. These events were caused by modification of treatment, especially the immunosuppressive regimen. Group A consisted of 75% men and 25% women. The frequency of symptomatic cholelithiasis was 11.7% in men and 27.3% in women, on average 19.5%. Mean time to cholelithiasis following HTX was 37.9 ±4.9 (Me = 41.5) months, 27.7 ±8.2 (Me = 30.0) months in women and 41.3 ±5.9 (Me = 41.5) months in men. The female to male ratio was 2.3: 1.
Conclusions: Cholelithiasis following HTX was significantly more frequent as compared with the non-transplant population. Patients with cholelithiasis required more aggressive immunosuppression because of more frequent episodes of acute transplant rejection. Patients with cholelithiasis significantly more frequently showed increased glycemia and blood lipids, which could be the side effect of intensive immunosuppressive therapy.
Keywords: cholelithiasis; cyclosporine A; immunosuppression; transplantation.
Figures
Similar articles
-
Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.Clin Transplant. 2000 Aug;14(4 Pt 2):413-20. doi: 10.1034/j.1399-0012.2000.14041002.x. Clin Transplant. 2000. PMID: 10946781
-
Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.Nephrol Dial Transplant. 2005 May;20(5):968-73. doi: 10.1093/ndt/gfh739. Epub 2005 Mar 1. Nephrol Dial Transplant. 2005. PMID: 15741208 Clinical Trial.
-
Increased incidence of cholelithiasis in heart transplant recipients receiving cyclosporine therapy.J Heart Transplant. 1990 Jul-Aug;9(4):404-7. J Heart Transplant. 1990. PMID: 2398436
-
Optimizing the immunosuppressive regimen in heart transplantation.J Heart Lung Transplant. 2004 May;23(5 Suppl):S207-13. doi: 10.1016/j.healun.2004.03.010. J Heart Lung Transplant. 2004. PMID: 15093807 Review.
-
Neoral use in the cardiac transplant recipient.Transplant Proc. 2000 May;32(3A Suppl):27S-44S. doi: 10.1016/s0041-1345(00)00862-9. Transplant Proc. 2000. PMID: 10814748 Review.
Cited by
-
Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation.Arch Med Sci. 2016 Oct 1;12(5):1158-1173. doi: 10.5114/aoms.2016.61919. Epub 2016 Aug 25. Arch Med Sci. 2016. PMID: 27695507 Free PMC article.
-
Coronary revascularization after heart transplant - the search for prognostic factors.Arch Med Sci. 2020 Apr 18;16(4):789-795. doi: 10.5114/aoms.2017.71847. eCollection 2020. Arch Med Sci. 2020. PMID: 32542079 Free PMC article.
References
-
- Task Force Members. McMurray JJ, Adamopoulos S, Anker SD. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847. - PubMed
-
- Aliabadi A, Cochrane AB, Zuckermann AO. Current strategies and future trends in immunosuppression after heart transplantation. Curr Opin Organ Transplant. 2012;17:540–5. - PubMed
-
- Lord RV, Ho S, Coleman MJ, et al. Cholecystectomy in cardiothoracic organ transplant recipients. Arch Surg. 1998;133:73–9. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources